Humming Bird Power, Precision & Agility

Where to find us

Generic placeholder image
About UCB Ventures
  1. UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. We make long term investments in early stage companies in the US and Europe. Our portfolio reflects our investment strategy.
  2. We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. We are seeking breakthrough innovations in next generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, RNA targeted therapeutics, and patient engagement solutions that significantly improve outcomes.
  3. We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies.

News

EsoBiotec

15 December 2021: EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient’s body.

Walden: targeting podocytes as linchpin for kidney function

Walden, 29 October 2021: targeting podocytes as linchpin for kidney function.

Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment

Syndesi, 21 October 2021: Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody

Belgium, 18 August 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

ExeVir’s CRO hunt for Phase II/III COVID-19 subQ antibody trial to start midyear, also USD 50– 100m Series B raise

13 Jul 2021. ExeVir Bio will open its doors to CRO pitches mid-year for a Phase II/III trial investigating its
subcutaneously administered neutralizing antibody XVR011 in outpatient COVID-19 patients, CEO
Torsten Mummenbrauer said. Decisions will be made in 2H21 for a 2Q22 trial start, he added.

Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy

18 Jun 2021. Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders